



Newsletter CLOZIN



Research

CLOZAPINE USERS

Creating a prediction
model for clozapine
response and side
effects

What's new?

Dear all,

There is a lot of news to mention.

We have a new name: CLOZIN, which stands for clozapine international. We also have a new logo. You can see it on the right side of this page.

We are also working on our website www.clozinstudy.com, where the graphs and documents will be available and updated regularly!

Update: recruitment and centers

The last news you have received from us was an update in February 2017 with news about recruitment of the centers and the joining patients. Currently, CLOZIN has **155 current users, 1 former user and 3 new users.**

The site Kuopio of prof. Tiihonen (Finland) and the site of dr. van Gool in the Western part of the Netherlands included their first patients.

Currently we have 3 types of centers:

1. Centers that are including patients. These are UMC Utrecht, GGZ-NHN, GGZ Rivierduinen, LMU Munich, Yulius, Altrecht (first patient soon) and Kuopio (Finland).
2. Centers that are currently in the submission phase. These are in Berlin, Innsbruck, the Vincent Van Gogh Institute, Reinier van Arkel and in Perth (Australia).
3. Centers that are interested and will probably participate: UMC Groningen, Lentis, AMC, Bergen and Trondheim (Norway). In addition, there are some sites that are checking the feasibility for their participation..

New Users

Unfortunately, as you can see, the number of new users is still small. We hope that this will change soon and that the number will increase. Again, when patients in Dutch centers will start using clozapine, all you have to do is email or call Cynthia Okhuijsen-Pfeifer (0652385871). There are no further procedures that you have to do for this part of the study. It's not a daily routine that patients start clozapine treatment, but we hope that you will keep this part of the study in mind!




UMC Utrecht

Email address:
c.pfeifer@umcutrecht.nl

clozin@umcutrecht.nl

Telephone number: +31887551460
P.O. Box 85500 | 3508 GA |
UTRECHT
www.umcutrecht.nl



* Please note that not all sites are currently screening for the former and/or new users part of the study.

GGZ-NHN has still recruited the most participants (45 patients). Kuopio recruited the most participants since last newsletter (22 patients), LMU has 9 new patients since last time and at UMCU we have 14 new patients. For the inclusion in the UMCU, we would like to thank the pharmacy network UPPER and the participating pharmacies for approaching the patients. In the Spring of 2018, we will organize a special symposium for them to thank them.

Note: If you experience problems or need any help, let us know! The interns meet patients at the UMCU and they're ready to support the other centers where necessary.

Goals for next time

Our goal was to have 150 patients. We made this goal, very good! for the next news-update, which you will receive in three months, is that we will have included 200 current/former users. That means that in the next four months we must enroll 50 more current/former users! With the new centers that have joined we are confident in reaching our new goal.

We really appreciate your part in this study to achieve our goal to make the treatment for psychotic patients better. Thank you and you will hear from us again in October!

If there are questions, remarks or anything else, please let us know on the email address: clozin@umcutrecht.nl

The CLOZIN team wishes everybody nice holidays!

Cynthia Okhuijsen-Pfeifer, Project Manager
Jurjen Luykx, Principal Investigator

Address:

UMC Utrecht, Psychiatrie, CLOZIN Study, Huispostnummer A01.126, Postbus 85500, 3508 GA Utrecht, Tel.: 088 755 1460

clozin@umcutrecht.nl